Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atherosclerotic cardiovascular disease. None of the trials...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) Vol. 400; no. 10365; pp. 1788 - 1801
Main Authors: Baigent, Colin, Emberson, JonathanR, Haynes, Richard, Herrington, William G., Judge, Parminder, Landray, Martin J., Mayne, Kaitlin J., Ng, Sarah Y.A., Preiss, David, Roddick, Alistair J., Staplin, Natalie, Zhu, Doreen, Anker, Stefan D., Bhatt, Deepak L., Brueckmann, Martina, Butler, Javed, Cherney, David Z.I., Green, Jennifer B., Hauske, Sibylle J., Heerspink, Hiddo J.L., Inzucchi, Silvio E., Jardine, Meg J., Liu, Chih-Chin, Mahaffey, Kenneth W., McCausland, Finnian R., McGuire, Darren K., McMurray, John J.V., Neal, Bruce, Neuen, Brendon L., Packer, Milton, Perkovic, Vlado, Sabatine, Marc S., Solomon, Scott D., Vaduganathan, Muthiah, Wanner, Christoph, Wheeler, David C., Wiviott, Stephen D., Zannad, Faiez
Format: Journal Article
Language:English
Published: England Elsevier Ltd 19.11.2022
Elsevier Limited
Subjects:
ISSN:0140-6736, 1474-547X, 1474-547X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first